Moreover, the tumor cell line used in this work has a high expression of PD-L1 and activation of BMDC with BLS increases the expression of the ligand, suggesting that the PD-1/PD-L1 pathway can limit the therapeutic outcome. Here, PDCD1 is linked to neoplasm.